News

Johnson & Johnson Announces Price Reduction for Bedaquiline

Earlier this week, Johnson & Johnson announced a reduction in the price for bedaquiline in low- and middle-income countries, as part of a collaboration with the Stop TB Partnership's Global Drug Facility (GDF). The immediate change in price will make bedaquiline available through the GDF at the price of USD340 per six-month treatment course for more than 135 eligible countries. This initiative was done with support from the Global Fund to Fight AIDS, Tuberculosis, and Malaria and USAID. 

The move has been praised by Médecins Sans Frontières as an important step forward in the fight against TB. 

“In a world filled with worrying news, this new agreement is a welcome development and one that will help us move closer to the United Nations High-Level Meeting target of treating 1.5 million people with DR-TB by 2022,” said Dr. Lucica Ditiu, M.D., Executive Director of the Stop TB Partnership.

To read more about Johnson & Johnson and the Stop TB Partnership's announcement on bedaquiline's price reduction, please visit the Stop TB Partnership website here

More News
29 Jul 2020
The WGND is announcing a call for applications to become a part of the WGND Core Group (CG). The CG provides leadership and sets the strategic direction for the work of the WGND. Addmitted applicants will begin their term in September 2020. Current CG membership information is available on the WGND...
18 Jun 2020
On May 21st, Antimicrbial Agents and Chemotherapy published an article on Otsuka's novel anti-tuberculosis compound, OPC-167832. This molecule, a DprE1 inhibitor, demonstrated potent bactericidal activity and exhibited significant combination effects in 2-drug combinations with delamanid,...
17 Jun 2020
On March 25th, Qurient announced the results of their Phase 2 Clinical Trial (ClinicalTrials.gov number, NCT03563599 ), which was a prospective, randomized, open-label trial for proof of concept in humans of their novel anti-tuberculosis drug, Telacebec (Q203). The trial involved 61 newly-diagnosed...